Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
0 hedge funds and large institutions have $0 invested in Inozyme Pharma in 2025 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 86 closing their positions.
78.32% less ownership
Funds ownership: 78.32% → 0% (-78%)
100% less funds holding
Funds holding: 86 → 0 (-86)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $202M → $0 (-$202M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 86
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$25.3M |
| 2 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$18M |
| 3 |
GCL
Glazer Capital LLC
New York
|
-$17.3M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$17.1M |
| 5 |
OBAM
ODDO BHF Asset Management
Paris,
France
|
-$12.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$14.9K | -3,725 | Closed |
|
77
Mirae Asset Global Investments
Seoul,
South Korea
| – | -$9.98K | -2,494 | Closed |
|
78
Barclays
London,
United Kingdom
| – | -$8K | -2,001 | Closed |
|
|
GFM
79
GF Fund Management
Guangzhou,
China
| – | -$6.18K | -1,544 | Closed |
|
80
BNP Paribas Financial Markets
Paris,
France
| – | -$6.02K | -1,505 | Closed |
|
81
Citigroup
New York
| – | -$5.56K | -1,390 | Closed |
|
82
Russell Investments Group
London,
United Kingdom
| – | -$4.14K | -1,035 | Closed |
|
|
EAM
83
Eukles Asset Management
Cincinnati,
Ohio
| – | -$4K | -1,000 | Closed |
|
84
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$3.68K | -919 | Closed |
|
|
EWA
85
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$1.08K | -270 | Closed |
|
|
SS
86
SBI Securities
Tokyo,
Japan
| – | -$136 | -34 | Closed |
|
INZY Hedge Fund Activity: Q3 2025 in Review
0 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q3 2025, worth a combined $0 — down 100% from $202M a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of INZY and 0 opened new positions — a net loss of 86 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Beryl Capital Management, exiting entirely with an estimated $25.3M sold.
- 0 institutional investors held Inozyme Pharma (INZY) as of Q3 2025, down from 86 in Q2 2025.
- Funds reported $0 of Inozyme Pharma stock for Q3 2025, down 100% quarter-over-quarter.
- 0 funds opened new Inozyme Pharma positions in Q3 2025 and 86 closed out, a net change of -86 holders.
- The largest Inozyme Pharma seller in Q3 2025 was Beryl Capital Management, an estimated $25.3M sold.
Based on aggregated 13F filings for Q3 2025.